Zaynich’s blockbuster potential lifts Wockhardt’s long-term outlook

June 2, 2026

Wockhardt’s novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of net losses. The drug, targeting multidrug-resistant bacteria, has a projected peak sales of $1.5 billion, potentially transforming the company’s financial outlook. Investors have responded positively, with the stock surging on the news.

More To Explore

Sensex falls over 100 pts, Nifty below 22,550 as market heads for 8th weekly loss, overtaking COVID crash. More pain ahead?

Indian equity benchmarks Sensex and Nifty fell for a fourth straight session on Thursday, heading for their eighth consecutive weekly loss. Driven by intense FII

October 1, 2026

NSE gets Sebi nod to launch corporate bond index futures

India’s National Stock Exchange has received a no-objection certificate to introduce futures contracts linked to a corporate bond index. This initiative, pending approval from the

October 1, 2026

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information.

The information on this website does not constitute investment advice or a recommendation or a solicitation to engage in any investment activity. This website and its content are not intended for residents of the UAE, US, Canada, Australia, UK, Russia, North Korea, China, Japan, Hong Kong, Singapore and Iran.

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003